Inovio Pharmaceuticals, Inc. (INO)
-NYSE MKT 0.68 
0.02(3.37%) 10:48AM EDT - Nasdaq Real Time Price
| Prev Close: | 0.70 |
|---|
| Open: | 0.70 |
|---|
| Bid: | 0.68 x 400 |
|---|
| Ask: | 0.68 x 9000 |
|---|
| 1y Target Est: | 1.50 |
|---|
| Beta: | 2.49 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.67 - 0.70 |
|---|
| 52wk Range: | 0.38 - 0.83 |
|---|
| Volume: | 1,211,982 |
|---|
| Avg Vol (3m): | 1,808,040 |
|---|
| Market Cap: | 121.73M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.15 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- INOVIO PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Amendments to AEDGAR Online(Tue, May 21)
- INOVIO PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Why You Should Be Investing In DNA Vaccination Technology And Inovio Pharmaceuticalsat Seeking Alpha(Thu, May 16)
- A Comprehensive Overview Of Active Electroporation Cancer Trialsat Seeking Alpha(Tue, May 14)
- Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge StudyPR Newswire(Tue, May 14)
- Inovio Pharmaceuticals: Why Best Therapeutic Vaccine Award In 2013?at Seeking Alpha(Tue, May 14)
- Inovio Pharmaceuticals Reports 2013 First Quarter Financial ResultsPR Newswire(Fri, May 10)
- INOVIO PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Narrower than Expected Loss at InfinityZacks(Thu, May 9)
- Corporate Profile Inovio Pharmaceuticals, Inc.WILink(Wed, May 8)
- Speculative Bio Stocks For Investorsat Seeking Alpha(Wed, May 8)
- Imminent Catalysts For Small Pharmaceuticalsat Seeking Alpha(Tue, May 7)
- Different Threats, Different Solutions, Many Ways To Make Moneyat Seeking Alpha(Thu, May 2)
- A Tale Of Three Pharmaceuticals: Getting Exciting In 2013at Seeking Alpha(Mon, Apr 29)
- RedChip Emerging Growth Showcase Takes Place May 1GlobeNewswire(Tue, Apr 23)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 32.46 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.15 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.04 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases.
View More